

Gender: Male | Birth year: 1950 | WHO: 0

Tumor: Lung - Adenocarcinoma | Lesions: Liver | Stage: IV

Summary

Clinical summary

Relevant systemic treatment history	1/2023-9/2024	Osimertinib
Relevant other oncological history	None	
Previous primary tumor	None	
Relevant non-oncological history	2022	Rheumatoid arthritis

Recent molecular results

Hartwig WGS results	No successful WGS could be performed on the submitted biopsy
IHC results	PD-L1: Score 1%

Example trials that are open and potentially eligible (0)

None

Example trials that are open and potentially eligible but currently have no slots available (1 cohort from 1 trial)

Trial	Cohort	Molecular	Warnings
METC 01 IEMOEN	Dose escalation - monotherapy		Hemoglobin 5.6 mmol/L below min of 6.0 mmol/L, History of rheumatoid arthritis, SOC not exhausted: at least platinum doublet remaining

Example trials that are open but for which additional genes need to be tested to evaluate eligibility (3 cohorts from 3 trials)

Trial	Cohort	Molecular	Warnings
METC 02 KAYRAS	Dose expansion - monotherapy - NSCLC		No molecular data with sufficient quality
METC 03 NO-SEE797ES	Dose escalation - monotherapy		No molecular data with sufficient quality
METC 04 TEDR1	Lung cancer C797S cohort		No molecular data with sufficient quality

Open cohorts with no slots available are shown in grey.

Trial Matching Summary

Example trials and cohorts that meet molecular requirements and may be eligible, but are closed (0)

None

Example trials and cohorts that are open but considered ineligible (1)

Trial	Cohort	Molecular	Ineligibility reasons
METC 02	Dose expansion - monotherapy -		No colorectal cancer
KAYRAS	Colorectum		

Open cohorts with no slots available are shown in grey.